Lumigan

Bimaprost ophthalmic solution is indicated for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

The recommended dose is one drop in the affected eye(s) once daily, either in the morning or in the evening. Use at the same time each day.

No adverse drug reactions (ADR's) specific for Bimaprost and Timolol combination have been observed in clinical studies. The ADR's have been limited to those for Bimaprost and Timolol. The majority of ADR's are mild in severity and none were serious, e.g., conjunctival hyperaemia, eye Pruritus, burning sensation, foreign body sensation in the eye, erythema of eyelid, eye pain, photophobia, eye irritation, eyelid oedema, lacrimation increased, growth of eyelashes.

Caution should be exercised in treating patients with severe and uncontrolled cardiovascular disease. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked. Patients with active intraocular inflammation, corneal diseases should be treated with caution.

Bimatoprost is a synthetic prostamide analogue with potent ocular hypotensive activity. It selectively mimics the effects of a naturally occurring substance, prostamide. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Timolol Maleate is a nonselective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant or local anaesthetic (membrane stabilizing) activity. Timolol is thought to work by decreasing the amount of aqueous humor formed in the eye.